Trials / Completed
CompletedNCT02634723
Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- Baxalta now part of Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing safety study is to evaluate the safety, immunogenicity, and effectiveness of ADVATE in previously untreated patients (PUPs) in China with moderate to severe hemophilia A.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Octocog alfa (recombinant human coagulation factor VIII) |
Timeline
- Start date
- 2015-12-23
- Primary completion
- 2016-06-30
- Completion
- 2016-06-30
- First posted
- 2015-12-18
- Last updated
- 2021-03-17
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02634723. Inclusion in this directory is not an endorsement.